Skip to main content
Công ty Cổ phần Dược Hậu Giang logo

Công ty Cổ phần Dược Hậu Giang — Investor Relations & Filings

Ticker · DHG ISIN · VN000000DHG0 HSX Manufacturing
Open in API
Filings indexed 182 across all filing types
Latest filing 2024-01-19 Earnings Release
Country VN Viet Nam
Listing HSX DHG

About Công ty Cổ phần Dược Hậu Giang

www.dhgpharma.com.vn

Công ty Cổ phần Dược Hậu Giang (DHG Pharma) is a leading pharmaceutical enterprise with over 50 years of experience. The company specializes in the research, development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products, including both supportive and treatment medications. DHG Pharma emphasizes the application of high technology and international production standards to ensure product quality. Key brands include Telfor, Bocalex, Natto DHA, Hapacol, and Biofermin, serving a broad consumer base. Committed to public health, DHG Pharma actively engages in community health initiatives and strives to provide high-quality, accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
DHG: Giải trình biến động kết quả kinh doanh quý 4/2023 so với quý 4/2022
Earnings Release Classification · 85% confidence The document is an official disclosure sent to the State Securities Commission and Ho Chi Minh Stock Exchange explaining the company’s Q4 2023 business results. It provides key highlights – net sales, profit before tax, profit after tax for Q4 and the full year, plus growth percentages and management commentary. It is not a full interim financial report (no full financial statements), but rather an initial announcement of quarterly/periodical results. Therefore, it fits the definition of an Earnings Release. Q4 2023
2024-01-19 Vietnamese
DHG: CBTT Quyết định HĐQT thông qua KHKD 2024 trình ĐHĐCĐ
Regulatory Filings Classification · 85% confidence The document is an “Extraordinary Information Disclosure” filed with the State Securities Commission and the Ho Chi Minh Stock Exchange, containing the Board’s decision and the FY2024 business plan that will be submitted at the Annual General Meeting. It does not contain actual financial statements or earnings results, nor is it a proxy statement, dividend notice, or other specialized filing. This type of regulatory announcement is best classified under the general “Regulatory Filings” category (RNS).
2023-12-29 Vietnamese
DHG: Quyết định của HĐQT về việc phê duyệt các giao dịch, hợp đồng thường niên giữa công ty với các tổ chức có liên quan năm 2024
Regulatory Filings Classification · 85% confidence The document is an extraordinary information disclosure filed with the State Securities Commission and Ho Chi Minh Stock Exchange. It contains a Board of Directors resolution approving annual related‐party transactions for 2024 – a routine regulatory announcement rather than a standalone financial report, earnings release, governance code, or capital transaction. It does not include substantive financial statements or a detailed presentation, nor is it a certification or an AGM material. Therefore, it falls under the general regulatory filings category.
2023-12-19 Vietnamese
DHG: Thông báo thay đổi nhân sự công ty
Board/Management Information Classification · 95% confidence The document is a formal announcement from DHG Pharmaceutical JSC to the State Securities Commission and Ho Chi Minh Stock Exchange regarding the appointment and dismissal of senior management roles (Supply Chain Director). It details Board of Directors decisions and effective dates for personnel changes. This matches the definition of Board/Management Information (MANG).
2023-12-19 Vietnamese
DHG: Giải trình chênh lệch lợi nhuận sau thuế quý 3/2023 so với quý 3/2022
Earnings Release Classification · 88% confidence The document is an extraordinary disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange explaining DHG Pharma’s Q3/2023 business results. It provides key summary figures (net sales, profit before and after tax for Q3 and 9 months) and narrative commentary but does not include full interim financial statements. This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results with key highlights only), rather than a comprehensive interim report. Q3 2023
2023-10-20 Vietnamese
DHG: Báo cáo kết quả giao dịch cổ phiếu của tổ chức có liên quan Công đoàn
Director's Dealing Classification · 91% confidence The document is a detailed report on share transactions conducted by an insider (internal person) and affiliated persons of DHG Pharma, disclosing pre‐ and post‐transaction holdings, transaction type, quantity, value, and trading period. This aligns with an insider dealing disclosure rather than a corporate financial report or announcement. Under our taxonomy, insider or director share transactions are classified as Director's Dealing (DIRS).
2023-10-13 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.